The constitutional challenge to the qui tam provisions of the False Claims Act (FCA) gained new momentum last week, this time from the U.S. Court of Appeals for the Fifth Circuit. On November 13, 2026, a Fifth Circuit panel in United States ex rel. Jackson v. Ventavia Research Group, LLC affirmed the government's dismissal of a relator's qui tam suit challenging the integrity of Pfizer's COVID-19 vaccine trials. Although the panel's holding on intervention and dismissal is unremarkable, the two concurring opinions are notable. Judge Don R. Willett wrote a lengthy concurrence expressing "serious doubts" that the qui tam device can survive Article II scrutiny, and Chief Judge Jennifer Walker Elrod concurred with Judge Willet, noting that his concurrence “raised some serious constitutional concerns with qui tam litigation,” which are "no doubt en banc worthy."
With these opinions, four current Fifth Circuit judges have now publicly questioned the constitutionality of the FCA's qui tam provisions. These questions come just two months after the Eleventh Circuit upheld the qui tam provisions against an Appointments Clause challenge in United States ex rel. Zafirov v. Florida Medical Associates, LLC, and signal the prospect of an eventual circuit split, and with it, Supreme Court review.
The Majority Opinion: A Routine Application of Polansky
The case was brought by a former regional clinical trial director at Ventavia, a contract site operator for Pfizer's Phase III COVID vaccine trial. Based on her roughly two-week tenure, relator alleged that Pfizer's submissions to the U.S. Food and Drug Administration (FDA) contained fabricated or manipulated data supporting the Emergency Use Authorization (EUA) and excluded serious adverse events and, therefore, the government’s subsequent purchase of Pfizer’s vaccine doses resulted in false claims, violating the FCA. Relator also brought a retaliation claim against Ventavia. The government originally declined to intervene. But after relator amended her complaint multiple times, the government finally moved to intervene and dismiss under 31 U.S.C. § 3730(c)(2)(A), arguing the claims lacked merit, were inconsistent with public health policy, and would impose substantial discovery burdens on the FDA, the U.S. Department of Health and Human Services, and the U.S. Department of Justice (DOJ).
Applying the Supreme Court's 2023 decision in United States ex rel. Polansky v. Executive Health Resources, Inc., the panel held that the FCA's "good cause" standard for later intervention is "a deliberately undemanding standard," that Federal Rule of Civil Procedure 24(b) does not apply, and that dismissal is governed by Rule 41's highly deferential framework. The panel also affirmed dismissal of the relator's retaliation claim. The panel did not address the constitutionality of the qui tam provisions because they were not raised at the district court or on appeal. The Fifth Circuit currently remains bound by its 2001 en banc decision in Riley v. St. Luke's Episcopal Hospital, which upheld the constitutionality of the qui tam provisions.
Judge Willett's Concurrence: "Riley Binds Us Today, But It Should Not Bind Us Forever"
Judge Willett framed the issue simply: "Who speaks for the United States in a lawsuit brought in its name? Under the False Claims Act, not always the United States." He pointed to the case's own "zig-zag journey," in which the government needed court permission to take back, and then defend on appeal, a case litigated in its name: "The statute worked just as Congress drafted it. And that is the concern."
The concurrence evaluates the constitutional case against the FCA’s qui tam device on Article II grounds and addresses the four main arguments made by qui tam supporters:
- Appointments Clause. The Appointments Clause prescribes how “Officers of the United States” must be appointed. The Supreme Court in Lucia v. SEC defined an “Officer” as one who “exercise[es] significant authority pursuant to the laws of the United States” and “occup[ies] a continuing position established by law.” Judge Willett found that a relator plainly exercises "significant authority," citing Buckley v. Valeo and the scale of FCA penalties, including DOJ's report that qui tam actions produced more than $5.3 billion of the $6.8 billion recovered in fiscal year 2025. He acknowledged that whether a relator occupies a "continuing position" is "a closer question," and cited the various circuits that have addressed the issue. He acknowledged that the Eleventh Circuit may have been right on the emolument point in Zafirov, but said other judges “have the better argument.” Ultimately, he did not resolve the question on whether the qui tam provisions violate the Appointments Clause.
- Vesting and Take Care Clauses. The Vesting Clause vests the executive power in the President. The Take Care Clause reinforces that vestment by charging the President to “take Care that the Laws be faithfully executed.” Judge Willett called these Clauses "a distinct—and stronger—problem" for the qui tam provisions. Drawing on the Supreme Court’s decisions in Seila Law v. CFPB, United States v. Arthrex, and Trump v. Slaughter, he reasoned that a relator in a declined case is not appointed, supervised, or removable by the President, need not follow DOJ policy, and owes no fiduciary duty to the United States. In his words, the relator exercises "executive power on a contingency fee."
- The defenses of qui tam. Judge Willett rejected four common arguments used to defend the qui tam provisions’ constitutionality: that the government's retained powers provide adequate control ("control that must be reclaimed is not control"); that the historical pedigree of qui tam statutes settles the question; that relators are mere assignees; and that the Property Clause supplies authority.
Judge Willett also noted that the legal landscape "has shifted materially" since Riley, citing the Supreme Court's recent Article II decisions and the views of three Justices who have questioned qui tam suits: Justice Thomas in his Polansky dissent, and Justices Kavanaugh and Barrett in Polansky and Justice Kavanaugh (joined by Justice Thomas) in Wisconsin Bell. He added that the en banc panel in Riley “did not have the benefit of those decisions, and I have serious doubts that its reasoning survives them intact.” He also pointed to the sharp rise in qui tam filings, including a record 1,297 new matters in fiscal year 2025, which DOJ attributes in part to data-mining relators.
Chief Judge Elrod's Concurrence: An En Banc Signal
Chief Judge Elrod's concurrence is brief but may prove the more consequential of the two. She joined the majority opinion in full but acknowledged Judge Willett’s concurrence and noted that "[i]n a proper case, it may be time for our en banc court to revisit Riley." Coming from the circuit's Chief Judge, that is a meaningful signal to litigants considering whether to preserve the issue.
Four Fifth Circuit Judges and Counting
Jackson brings to four the number of active Fifth Circuit judges who have publicly questioned Riley's constitutional footing. In 2025, Judge Stuart Kyle Duncan, concurring in United States ex rel. Montcrief v. Peripheral Vascular Associates, identified "constitutional flaws in the FCA's qui tam device, which our precedent prevents us from addressing." Later that year, Judge James C. Ho, concurring in United States ex rel. Gentry v. Encompass Health, wrote that Judge Duncan "has already called on our court to revisit Riley. Had I been on that panel, I would have joined him." Judges Willett and Elrod now join that group. Judge Willett also noted that Judge Jerry E. Smith raised similar concerns in his Riley dissent.
Because Riley is an en banc decision, only the en banc court (or the Supreme Court) can overrule it. Four judges do not make an en banc majority, and concurrences do not necessarily predict how any judge would rule on a fully briefed record. Still, the trajectory is hard to miss: the Fifth Circuit increasingly appears receptive to a properly preserved Article II challenge, and defendants can be expected to raise the issue more often, hoping to present the "proper case" Chief Judge Elrod described.
The Contrast with Zafirov and a Potential Circuit Split
The Fifth Circuit concurrences contrast with the Eleventh Circuit's September 1, 2026 decision in Zafirov, which we covered in an earlier blog post. There, the Eleventh Circuit reversed Judge Kathryn Kimball Mizelle's ruling that the qui tam provisions violate the Appointments Clause, holding that relators do not occupy a "continuing position" because they "have temporary tenure and duration, no continuing emolument, and personal duties." The Eleventh Circuit addressed only the Appointments Clause and remanded for consideration of the defendants' Take Care and Vesting Clause arguments.
Judge Willett engaged directly with Zafirov, calling it a "scholarly opinion" that "identifies real difficulties" but respectfully disagreeing. His concurrence suggests that the Take Care and Vesting Clause theories, the very questions Zafirov left open, may be the stronger ground for challenge. Those theories remain live on remand in Zafirov and in other pending cases, including the Third Circuit appeal in Penelow v. Janssen Products, LP.
At present, there is no circuit split. Every court of appeals to rule on the question has upheld the qui tam provisions, and the Sixth Circuit in January 2026 declined an interlocutory appeal on the issue, citing its own 1994 precedent. As we noted when Zafirov was decided, without a split it is hard to see the Supreme Court taking up such a controversial matter. A Fifth Circuit en banc decision overruling Riley, or a ruling from another circuit adopting a Take Care or Vesting Clause theory, would change that calculus. In the meantime, the relator in Jackson has reportedly indicated she will petition the Supreme Court, although her appeal did not present the constitutional question.
What This Means for Health Care Companies
Health care providers, suppliers, and life sciences companies remain the most frequent qui tam targets, so this debate has outsized significance for the industry. While the qui tam provisions remain fully enforceable in every circuit, companies should consider the following:
- Exposure has not changed yet. Riley remains binding in the Fifth Circuit, and no appellate court has held the qui tam provisions unconstitutional. Companies should continue to treat declined qui tam cases as a serious risk, particularly given the record pace of filings and DOJ's May 2026 initiative to expedite review of qui tam complaints involving state-administered benefit programs such as Medicaid and CHIP, which DOJ expects will increase the number of matters "primarily litigated by relators."
- Preserve the constitutional defense. Defendants in declined qui tam cases, particularly in the Fifth and Eleventh Circuits, should consider raising Appointments, Take Care, and Vesting Clause challenges at the motion to dismiss stage. Doing so preserves the issue for appellate review and may support a request for a stay or certification for interlocutory appeal, although appellate courts bound by precedent have been reluctant to accept such appeals.
- Consider forum and posture. The challenge targets declined cases in which the relator controls the litigation. Where the government intervenes, the Article II arguments carry far less force. Companies should factor the likelihood of intervention and the pending forum into their defense strategy and settlement analysis.
- Do not relax compliance. Even if relator authority were ultimately curtailed, the government retains full authority to bring FCA actions, and the FCA enjoys broad bipartisan support. A successful constitutional challenge could prompt legislative changes or increased government intervention rather than reduced enforcement. Robust compliance programs, internal reporting channels, and prompt investigation of internal complaints remain the most effective protection.
- Monitor key developments. These include any en banc petition in the Fifth Circuit, the Zafirov remand and any further review, the Third Circuit's decision in Penelow, and any petition for certiorari presenting the issue.
Ultimately, the constitutionality of the qui tam provisions remains an open and evolving question. The Jackson concurrences do not change the law, but they meaningfully increase the likelihood that the Fifth Circuit, and eventually the Supreme Court, will take up the issue on the merits.
Reed Smith will continue to follow developments in qui tam actions and the constitutionality of the False Claims Act. If you have questions about this decision or the False Claims Act, please contact the authors or the Reed Smith attorneys with whom you work.
/Passle/MediaLibrary/Images/2026-05-27-21-04-42-885-6a175c6ad53a49a94764380a.jpg)